Observer-Reported Communication Ability (ORCA)
The ORCA study will adapt a communications-assessment tool for use in clinical trials to determine the efficacy of Rett treatments. The study has successfully completed Phase 1 and Phase 2 and the data is currently being analyzed. We are tremendously grateful to the nearly 300 Rett parents who participated in the study. We will continue to update the Rett community about ORCA progress, and we hope to have the assessment tool available soon.
ORCA Study Addresses Communication, a Top Concern of Rett Parents
Most parents of non-verbal children would agree that communication is at the top of the symptoms list they would like addressed. Currently a communication-focused assessment tool does not exist for Rett. However, one does exist for Angelman syndrome (a disorder with similarities to Rett), called the Observer-Reported Communication Ability (ORCA). We are leveraging the efforts already invested in ORCA by the Angelman community to adapt ORCA for Rett.
The ORCA was developed by the Center for Health Measurement (CHM) at Duke University School of Medicine. It includes 72 questions that capture various types of expressive, receptive, and pragmatic forms of communication and places individuals on a continuum of communication ability that detects changes over time. The ORCA does not rely on speech, but allows gestures, vocalizations, and use of aids to capture communication ability. It takes about 10 to 15 minutes for a parent or caregiver to complete the measure independently, and it does not require the help of a clinician or speech language pathologist. The ORCA is now being used in clinical trials and natural history studies for individuals with Angelman syndrome.
RSRT has provided funding to Dr. Reeve, the director of CHM, and his team to develop the ORCA for Rett. During Phase 1 a number of one-on-one interviews with parents of individuals with Rett took place. Phase 2 which enrolled almost 300 Rett syndrome parents to complete the newly revised ORCA. The data contributed by parents is now being analyzed. The ORCA will be available soon to the clinical and biopharmaceutical community to test it out in clinical care or clinical trial settings.